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bjectives The aim of this study was to examine the incidence of clinical events after implantation
f the TAXUS Express (Boston Scientiﬁc Corporation, Natick, Massachusetts) paclitaxel-eluting stent
n saphenous vein graft (SVG) lesions in an unselected patient population.
ackground Saphenous vein grafts have 1-year occlusion rates of 12% to 20%, with 50% failure by 7
o 10 years. Many diseased SVGs are treated by percutaneous coronary intervention to avoid higher-risk
eoperation, but bare-metal stents have 35% to 40% historical SVG restenosis rates by 18 months. Re-
orted outcomes of drug-eluting stents in SVG lesions are limited and mainly retrospective.
ethods The ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program
ompiled data on 7,492 patients receiving 1 TAXUS Express (Boston Scientiﬁc) stent, including 474
atients with SVG. All cardiac events were monitored with independent adjudication of end points.
atients enrolled at procedure start with no mandated inclusion/exclusion criteria.
esults The ARRIVE SVG patient 2-year follow-up was 96% complete (457 of 474). The SVG patients had
igniﬁcantly more baseline comorbidities/complex disease than simple-use patients (n  2,698) undergo-
ng native coronary intervention or other expanded-use patients (n  4,320 without SVG patients). They
ad higher 2-year rates of mortality (10.9% vs. 4.2%, p  0.001), myocardial infarction (5.3% vs. 2.2%,
 0.001), and Academic Research Consortium deﬁnite/probable stent thrombosis (4.7% vs. 1.4%, p 
.001) than the simple-use group. They also had higher 2-year adverse event rates, including signiﬁcantly
ore mortality (10.9% vs. 7.5%, p  0.008) than other expanded-use patients.
onclusions The ARRIVE SVG patients have signiﬁcantly different baseline risk and higher clinical risk
hrough 2 years than simple-use and other expanded-use patients. Nonetheless, compared with historical
VG revascularization rates, treatment with paclitaxel-eluting stent seems to offer a reasonable therapeu-
ic option in this high-risk group. (TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multicenter Safety
urveillance Program; NCT00569491) and (TAXUS ARRIVE 2: A Multicenter Safety Surveillance
rogram; NCT00569751) (J Am Coll Cardiol Intv 2010;3:742–50) © 2010 by the American College of
ardiology Foundation
rom the *VA North Texas Healthcare System and University of Texas Southwestern Medical Center at Dallas, Dallas, Texas;
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743aphenous vein grafts (SVG) historically have had occlusion
ates of approximately 12% to 20% after 1 year, progressing
o over 50% by 7 to 10 years (1–4). Recently, a large
andomized controlled trial (RCT) reported per-patient
ngiographic vein graft failure rates of 40% by 18 months
5). Given the higher risk of adverse outcomes associated
ith repeat bypass surgery (6), percutaneous coronary inter-
ention (PCI) is generally the preferred revascularization
ption for patients with recurrent graft-related disease. In
he U.S., 6% to 10% of all PCI are performed in SVGs (7).
atients undergoing PCI of SVG lesions with or without
are-metal stents (BMS) also have a high risk for adverse
linical events due to restenosis or thrombus at the treat-
ent site and/or disease progression elsewhere in the SVG
6,8–12). Implantation of drug-eluting stents (DES) has
mproved short- and mid-term SVG clinical outcomes
ompared with BMS in some studies (13–29), but much of
he available data are retrospective. Two small prospective
CTs have reported significantly lower angiographic reste-
osis with DES compared with BMS in SVGs during a
edian follow-up of 18 to 32 months (30–32).
In the absence of large RCTs of SVG stenting, registries
an provide insight into the clinical outcomes of such
atients. The ARRIVE (TAXUS Peri-Approval Registry:
Multicenter Safety Surveillance) Program captured usage
atterns and outcomes in 7,492 patients, including 474
atients who underwent SVG stenting (33,34). With data
rom the ARRIVE program, we evaluated 2-year clinical
utcomes after SVG DES implantation, compared them
ith outcomes in patients receiving the same DES in
oncomplex or complex native coronary lesions, and exam-
ned outcomes in the SVG subgroup in relation to other
ublished studies.
ethods
tudy design, data collection, and follow-up. The TAXUS
RRIVE Program, which has been described previously,
ncluded 2 prospective, multicenter U.S. safety surveil-
ance registries (ARRIVE 1 [50 sites, February to May
004] and ARRIVE 2 [53 sites, October 2004 to October
005]) (33,34). The program was designed to enroll
onsecutive patients treated with the slow-release
AXUS Express (Boston Scientific Corporation, Natick,
assachusetts) paclitaxel-eluting stent (PES). No spe-
ific inclusion/exclusion criteria were mandated. Patients
ho gave informed consent for participation under a
rotocol approved by the local institutional review board
n conformity with the Declaration of Helsinki and U.S.
ood and Drug Administration guidelines were enrolled
t the time of procedure initiation. Follow-up angiogra-
hy was performed at operator discretion. Dual antiplate-et therapy (DAPT) with aspirin and clopidogrel or siclopidine was begun before or immediately after the
rocedure. Aspirin was continued indefinitely and thien-
pyridine was recommended for 6 months per the
AXUS Express (Boston Scientific Corporation) stent
irections For Use. At 1 year, 67.7% of ARRIVE
atients (4,687 of 6,927) were taking DAPT with 53.1%
3,487 of 6,569) at 2 years (35). The SVG patients were
omewhat higher at 74.2% (322 of 434) and 66.6% (269
f 404), respectively. Both studies are registered (see
linical trial registry data after abstract; identifiers
CT00569491 and NCT00569751).
An independent clinical events committee with no finan-
ial conflicts of interest with the sponsor determined the
elationship of reported cardiac events to the study device;
n event was deemed related to the TAXUS stent if it
ccurred at the stented segment
r if the relationship to the stent
ould not be excluded on the
asis of existing information
33). Data were source verified
or death, major cardiac events
cardiac death, myocardial in-
arction [MI], target vessel re-
ascularization [TVR], target le-
ion revascularization [TLR]
defined as “TAXUS-stent-
elated” TVR]), and stent
hrombosis (ST) along with an
dditional 10% to 20%/site ran-
om sampling of patients. Adju-
ication of ST per the Academic
esearch Consortium (ARC)
efinite/probable definition (36)
as performed by an indepen-
ent committee at the Harvard
linical Research Institute.
tatistical analysis. For baseline
ariables, simple proportions
ere used with 2-sided p values
rom a Student t test for continuous variables (summa-
ized as mean  1 SD) and chi-square test for discrete
ariables (presented as frequencies and group percent-
ges). Statistical analyses of events were carried out on
he basis of the clinical events committee assessment of
elation to the TAXUS stent. The Kaplan-Meier product
ethod (log-rank p value) was used for time-to-event
nalyses. Backward Cox proportional hazards regression
as used to assess 41 variables (Appendix) to identify
redictors of major events; the threshold to remain in the
odel was p  0.10. All analyses were performed with
AS System Software version 8.0 or higher (SAS Insti-
ute, Cary, North Carolina); p  0.05 was considered
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RCT  randomized
controlled trial
SES  sirolimus-eluting
stent
ST  stent thrombosis
SVG  saphenous vein graft
TLR  target lesion
revascularization
TVR  target vessel
revascularizationtatistically significant.
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744esults
atient and procedural characteristics. Of 7,492 total
RRIVE patients, 474 (6.3%) underwent stenting of an
VG lesion (578 lesions). Most ARRIVE cases (n 4,794)
ere considered expanded-use on the basis of patient and/or
esion characteristics outside the simple-use subgroup (n 
,698) who would have met the criteria for inclusion in the
AXUS IV pivotal trial (37). As shown in Table 1, SVG
atients had significantly more baseline comorbidities and
omplex disease than the simple-use subgroup as well as the
ohort of other expanded-use, non-SVG cases (n  4,320).
atients who underwent SVG stenting were mostly men
nd had a high prevalence of diabetes, prior MI, and prior
CI. Table 2 shows procedural data for the SVG subgroup.
rimary stenting was performed in approximately one-half
f SVG lesions, and an embolic protection device was used
n 29% of SVG patients at the discretion of the physician.
linical outcomes. Among ARRIVE SVG patients, clinical
ollow-up was available in 98% (465 of 474) at 1 year and
6% (457 of 474) at 2 years. Clinical outcomes through 2
ears (Kaplan-Meier analysis) in the SVG, the simple-use,
nd the other expanded-use (minus SVG) cohorts are
hown in Table 3 and Figure 1. Rates for mortality, all MI,
nd ST were significantly higher in the SVG subgroup than
Table 1. Comparison of Baseline Patient and Lesion Characteristics in ARRIV
Variable
Vein Graft
(n  474 Patients)
(n  578 Lesions)
Simple U
(n  2,698 P
(n  3,112 L
Patient characteristics
Age (yrs) 68.0 10.4 (474) 63.0 11.5 (
Male 80.8% (383) 65.9% (1,7
Hypertension 79.7% (378) 75.4% (2,0
Hyperlipidemia 88.6% (420) 74.4% (2,0
Diabetes mellitus† 40.3% (191) 29.8% (80
Oral medications 29.5% (140) 21.8% (58
Insulin 15.0% (71) 8.9% (24
Smoking at baseline 12.4% (59) 24.2% (65
Prior MI 48.9% (232) 26.9% (72
Prior PCI 48.1% (228) 34.5% (93
Prior stroke 10.3% (49) 5.0% (13
Lesion characteristics
RVD (mm) 3.3 0.5 (578) 3.0 0.4 (3
Lesion length (mm) 16.7 12.6 (575) 13.7 5.8 (3
B2/C lesion 58.3% (337) 33.3% (1,0
Diameter stenosis (%) 86.9 10.1 (578) 84.4 10.4 (
Moderate/severe calciﬁcation (%) 7.3% (42) 0.0% (0)
Restenotic lesions 11.6% (67) 0.0% (0)
Data are % (n) or mean SD (n); p values are chi-square test (binary) or t test (continuous). *Simple
bifurcation, cardiogenic shock, chronic total occlusion, prior brachytherapy, vein graft stenting, in-s
lesion (28mm),moderate/severe calcification,multivessel stenting (meanof 2.1 vessels/patient), o
mm). Expanded-use cases are those not described as simple-use. †Includes patients treated with dARRIVE TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance Program; PCI percutaneousn simple-use patients, although Q-wave MI was not.
ortality was also significantly higher for the SVG cohort
han the subgroup of other expanded-use patients. From
ear 1 to year 2, mortality increased among SVG patients
5.1% and 5.8%, respectively), whereas MI was higher in
ear 1 (3.5% and 1.8%), and ST was equal (2.4% and 2.3%).
y comparison, in the simple-use subgroup, year 1 rates
ere higher for mortality (2.3% and 1.9%), MI (1.4% and
.8%), and ST (0.9% and 0.5%). The expanded-use (minus
VG) cohort also had higher event rates in year 1 for
ortality (4.1% and 3.4%), MI (2.5% and 1.2%), and ST
2.2% and 1.0%). In the SVG cohort, early (0 to 30 days)
T was 1.3% (6 of 474), and late (31 days to 1 year) ST was
.1% (5 of 467), as reported previously (35). Among the 21
RRIVE SVG patients suffering an ST event, 16 under-
ent subsequent revascularization within 30 days, all of
hich were TLR. Early and late ST were 0.4% and 0.5%,
espectively, in the simple-use subgroup (35) and 1.4% and
.8%, respectively, in the expanded-use minus SVG cohort.
In patients with SVG stenting, the 2-year rate of target
essel failure (defined as cardiac death, MI, and TVR) was
ignificantly higher than in the simple-use cohort (19.9% vs.
.6%, respectively, p  0.001) or the subgroup of other
xpanded-use patients (19.9% vs. 14.8%, p  0.005). In the
Graft, Simple Use, and Other Expanded Use (Minus Vein Graft) Cohorts
)
)
Other Expanded Use
(Minus Vein Graft)*
(n  4,320 Patients)
(n  6,874 Lesions)
p Value
Vein Graft vs.
Simple Use
p Value
Vein Graft vs.
Other Expanded Use
(Minus Vein Graft)
64.6 11.9 (4,320) 0.001 0.001
66.7% (2,883) 0.001 0.001
75.9% (3,279) 0.04 0.06
75.2% (3,250) 0.001 0.001
31.8% (1,372) 0.001 0.001
22.9% (989) 0.001 0.001
10.5% (452) 0.001 0.003
24.4% (1,053) 0.001 0.001
40.9% (1,765) 0.001 0.001
36.3% (1,567) 0.001 0.001
6.6% (283) 0.001 0.002
3.0 0.5 (6,873) 0.001 0.001
16.4 10.0 (6,848) 0.001 0.48
57.2% (3,927/6,870) 0.001 0.59
85.7 11.2 (6,871) 0.001 0.01
27.1% (1,863) 0.001 0.001
6.9% (475) 0.001 0.001
es, with or without diabetes, excluded 1 or more of the following: acute myocardial infarction (MI);
tenosis, large vessel (reference vessel diameter [RVD]3.75 mm), left main disease/stenting, long
ion, renal disease (serumcreatinine3.0mg/dl or dialysis), severe tortuosity, small vessel (RVD2.5
cise plus those treated with oral medications and/or insulin.E Vein
se*
atients
esions
2,698)
77)
34)
07)
5)
9)
1)
2)
5)
0)
5)
,110)
,103)
35)
3,111)
-use cas
tent res
stial les
iet/exercoronary intervention.
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745Table 2. ARRIVE Vein Graft Stenting Procedural Characteristics
Variable
ARRIVE Vein Graft Stenting
(474 Patients; 524 Vessels; 578 Lesions)
Clinical procedural success* 95.3% (462)
Technical success† 99.0% (483)
Implant success‡ 94.4% (458)
Pre-dilation 48.3% (279)
Recipient vessel for graft§
LAD/diagonal 26.3% (152/578)
Circumﬂex/OM 38.1% (220/578)
RCA/PDA 35.5% (205/578)
Vessels treated/patient
1 89.7% (425)
2 10.1% (48)
3 0.2% (1)
Lesions treated/patient
1 81.0% (384)
2 16.5% (78)
3 2.5% (12)
Stents/vessel 1.4 0.7 (522) (1.0, 6.0)
Stents/lesion 1.2 0.6 (576) (1.0, 6.0)
Total stent length/lesion (mm) 24.0 16.7 (576) (8.0, 180.0)
Stents/patient 1.5 0.9 (473) (1.0, 7.0)
1 67.1% (318)
2 21.9% (104)
3 10.8% (51)
Stent length/patient (mm) 29.3 21.0 (473) (8.0, 180.0)
Embolic protection device 28.9% (137)
Pre-stenting TIMI ﬂow grade (per lesion)
0 3.1% (18)
1 3.5% (20)
2 19.7% (114)
3 73.7% (426)
Post-stenting TIMI ﬂow grade (per lesion)
0 0.2% (1)
1 0.0% (0)
2 1.2% (7)
3 98.6% (569)
Post-dilation (per lesion) 37.9% (219)
Post-stent balloon pressure (atm) 15.9 4.0 (218) (3.0, 25.0)
Slow ﬂow/no ﬂow after PCI 6.6% (38)
Post-procedure %DS 1.3 6.6 (576) (0.0, 100.0)
Procedural medications
sGPIIb/IIIa inhibitor 44.3% (210)
Bivalirudin 37.3% (177)
Aspirin 71.3% (338)
Clopidogrel 81.0% (384)
DAPT 67.7% (321)
Data are presented as % (n) or mean  SD (n) (minimum, maximum). *Clinical procedural success was defined as mean lesion diameter stenosis
30%, a Thrombolysis In Myocardial Infarction (TIMI) flow grade of 3 as visually assessed by the physician, and no in-hospital clinical events
committee-adjudicated events (n 485). †Technical success was defined as a successful delivery or deployment of the study stent to the target
lesion without device malfunction (n 488). ‡Implant success was defined as the percentage of implant procedures exhibiting both procedural
and technical success (n 485). §Left main in 1 patient (0.2%). 1 patient received ticlopidine (0.2%).
DAPT  dual antiplatelet therapy (aspirin plus clopidogrel/ticlopidine); DS  diameter stenosis; LAD  left anterior descending artery;OM obtuse marginal; PDA posterior descending artery; RCA right coronary artery; other abbreviations as in Table 1.
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746VG cohort, target vessel failure was higher in the first year
11.9%) than during the second year (8.0%), reflecting
igher first-year rates for graft-related TVR (8.6% com-
ared with 5.4% in year 2) (Fig. 1). Although much of the
bserved graft-related TVR was driven by in-stent resteno-
is (5.7% in year 1, 4.5% in year 2), progressive disease in the
VG outside the stent is a well-known failure mode for
VG intervention, and non-TLR TVR accounted for 34%
f TVR in year 1 and 17% of TVR in year 2. In the overall
RRIVE population, SVG stenting was an independent
redictor (1.5- to 2-fold increased risk) for death, cardiac
eath, MI, TLR, and ST through 2 years (Table 4). The
ncreased risk for TLR was driven solely by a 2-fold
ncreased risk in year 2. The increased risk for ST was driven
xclusively by a 3-fold increased risk for very late ST (1
ear).
Table 3. Death and MI in ARRIVE Vein Graft, Simple-Use, and Other Expan
Clinical Event*
Vein Graft
(n  474 Patients)
Simple Use*
(n  2,698 Patients)
1 yr 2 yrs 1 yr 2 yrs
Death 5.1 (24) 10.9 (50) 2.3 (60) 4.2 (108)
Cardiac 3.5 (16) 7.1 (32) 1.3 (33) 2.1 (54)
MI 3.5 (16) 5.3 (24) 1.4 (36) 2.2 (56)
Q-wave MI 0.7 (3) 1.4 (6) 0.5 (12) 0.7 (19)
Data are from Kaplan-Meier analysis and are expressed as % (n); p values are log-rank (0 to 2 years)
MImyocardial infarction; other abbreviations as in Table 1.
Figure 1. Death/MI, ST, and Revascularization Through 2 Years in the ARR
Graft) Subgroups
Cohorts were ARRIVE vein graft (n  474) (red line), ARRIVE simple use (n  2
(green line). Simple use and expanded use cohorts are deﬁned in Table 1. Gra
Target lesion revascularization was deﬁned as “TAXUS-stent-related” target ves
Stent thrombosis (ST) is per Academic Research Consortium (ARC) deﬁnite/pro
graft and simple use cohorts and between vein graft and other expanded use (minuiscussion
he ARRIVE registries gathered data on 7,492 patients
reated in routine practice with the TAXUS Express (Bos-
on Scientific Corporation) PES, including 474 patients
ho underwent SVG stenting (33,34). These SVG patients
ad significantly more comorbidities and a higher risk of
linical events through 2-year follow-up than the subgroup
f simple-use patients (n  2,698) who would have been
ligible for the TAXUS IV pivotal trial (37). They also had
imilar or greater comorbidities and higher adverse event
ates than the cohort of other (non-SVG) expanded-use
atients (n  4,320). However, repeat revascularization
fter PES implantation in ARRIVE SVG patients (14.0%
VR and 10.2% TLR through 2 years) was still lower than
he historical 35% to 40% failure rate of BMS in SVG at 18
se (Minus Vein Graft) Cohorts
Other Expanded Use
(Minus Vein Graft)*
(n  4,320 Patients) p Value
Vein Graft vs.
Simple-Use
p Value
Vein Graft vs.
Other Expanded-Use
(Minus Vein Graft)1 yr 2 yrs
4.1 (173) 7.5 (303) 0.001 0.008
2.6 (110) 4.3 (174) 0.001 0.008
2.5 (103) 3.7 (149) 0.001 0.081
0.7 (31) 1.1 (45) 0.19 0.67
e use and expanded use are defined in Table 1.
ein Graft, Simple Use, and Other Expanded-Use (Minus Vein
(blue line), and ARRIVE other expanded use (minus vein graft, n  4,320)
ted revascularization is shown for the saphenous vein graft (SVG) cohort.
ascularization, given the absence of a central angiographic core laboratory.
deﬁnitions (36). The p values (log-rank) are for the comparison between veinded-U
. *SimplIVE V
,698)
ft-rela
sel rev
bables vein graft) cohorts; error bars are  1.5 SEM. MI  myocardial infarction.
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747onths (4,14). The ARRIVE revascularization outcomes
ere similar to what was observed with PES in the
ulticenter prospective SOS (Stenting Of Saphenous vein
rafts) RCT at 2 years where TVR was significantly lower
ith TAXUS than with BMS (16% vs. 35%, respectively)
32).
Long-term data have shown a reduction in TLR with DES
ompared with BMS with no significant difference in death or
I in the inherently lower-risk patients/native coronary le-
ions generally studied in RCTs (38). The first prospective trial
f DES in SVGs, the RRISC (Reduction of Restenosis In
aphenous vein grafts with CYPHER sirolimus-eluting stent)
rial (n 75), also reported a lower 6-month rate of ischemia-
riven TVR for sirolimus-eluting stent (SES) compared with
MS (5.3% vs. 27.0%, respectively, p  0.012) as well as
educed neointimal hyperplasia volume (30,39). However, after
median of 32 months, the incidence of TVR was similar in
he 2 study groups due to late catch-up in the SES group (34%
or SES vs. 38% for BMS, p 0.74) (31). Outcomes at 2 years
n ARRIVE SVG patients (14.0% TVR) are similar to that of
ES patients in SOS (16% TVR), suggesting that “real-world”
ES use in SVG lesions might have a lower revascularization
ate than BMS and potentially SES, at least through 2 years
32,40). The ongoing BASKETSAVAGE study (Clinical
rials Identifier, NCT00595647) will compare TAXUS with
MS in SVG when used in conjunction with a glycoprotein
Ib/IIIa inhibitor and a distal filter system and should provide
dditional randomized trial data regarding SVG stenting.
Reported revascularization rates among SVG patients
eceiving DES in observational studies have been varied.
ne single center study reported a 19% TVR rate at 1
ear among 110 consecutive SVG patients (41). In
Table 4. Vein Graft Stenting as an Independent Risk Factor for Adverse
Events in ARRIVE
Event Type
(n  7,492 ARRIVE Patients)
Hazard Ratio
(95% CI)
Death (0–2 yrs, n  461) 1.43 (1.05–1.96)
Cardiac death (0–2 yrs, n  260) 1.61 (1.09–2.37)
MI (0–2 yrs, n  229) 1.86 (1.18–2.94)
TVR (0–2 yrs, n  715) 1.60 (1.23–2.10)
TVR (0–1 yr, n  492) 1.50 (1.07–2.11)
TVR (1–2 yrs, n  223) 1.68 (1.12–2.53)
TLR (0–2 yrs, n  545) 1.76 (1.30–2.39)
TLR (0–1 yr, n  373) NS*
TLR (1–2 yrs, n  172) 1.77 (1.13–2.79)
ST (0–2 yrs, n  184) 2.03 (1.27–3.23)
Early ST (0–30 days, n  77) NS*
Late ST (31 days–1 yr, n  51) NS*
Very Late ST (1–2 yrs, n  56) 2.90 (1.44–5.83)
*p 0.05.
ST stent thrombosis; TLR target lesion revascularization (TAXUS stent-related target vessel
revascularization [TVR]).nother single-center registry, TVR was 13% at 1 year, tith disease progression in the nonstented segment
ccounting for one-third of revascularizations (42).
hrough 2 years in the STENT (Strategic Transcatheter
valuation of New Therapies) registry, TVR with DES
as 18.2%, similar to that in the ARRIVE program, with
lower event rate and propensity adjusted hazard ratio
ompared with BMS (7). Reports from nonrandomized
omparisons of DES and BMS in SVG lesions of various
ges have also communicated diverse results (14–29,43,44).
any are retrospective, and some are limited by short follow-
p. Approximately one-half have shown some significant
evascularization benefit with DES; others have suggested no
enefit at all (45).
Late outcomes (median follow-up of 32 months) in the
RISC trial have raised concerns about a significant albeit
ot fully understood mortality excess in SVG patients
eceiving SES (31). Higher mortality was not observed,
owever, in the multicenter 350-patient case-control study
omparing SES with a variety of BMS in clinical use during
he 2000s (16). Through 2 years in the SOS trial, there were
umerically more deaths overall with PES versus BMS (5
s. 2, respectively), but the BMS group had more cardiac
eaths (2 vs. 1). Annual mortality among ARRIVE SVG
atients was approximately 5.5%; although higher than in
imple-use patients, this rate was comparable to results from
,119 patients in the Duke Cardiovascular Disease Database
here annual mortality after SVG stenting with BMS
median follow-up of 4.8 years) ranged from 5.7% to 8.6%
46). Among SVG patients receiving DES in the STENT
egistry, mortality was 4.6% at 9 months and 8.2% at 2 years
7). In a recently reported observational study, SVG patient
ortality through 4 years was not significantly different
etween DES and BMS (22.5% vs. 27.0%, respectively, p
.65) (28). The data overall suggest that, although DES
ight not increase mortality relative to BMS, they also do
ot prevent the high annual mortality rate seen in patients
fter SVG stenting with BMS. Among ARRIVE SVG
atients, medically treated diabetes was a significant predic-
or of 2-year cardiac death (hazard ratio: 2.11, 95% confi-
ence interval: 1.02 to 4.36, p  0.044). Many late events
fter SVG stenting are likely to reflect background disease
ctivity outside the stented segment, as has been reported
or lower-risk patients participating in RCTs (47,48).
Early ST was higher in the ARRIVE SVG subgroup
ompared with the simple-use cohort (38), and through 2
ears, ARRIVE SVG patients had a significantly higher ST
ncidence (Fig. 1). Among the 21 ARRIVE SVG patients
uffering an ST event, however, all 16 revascularizations per-
ormed were TLR. Stent thrombosis could be related to
n-stent restenosis but might also result from SVG disease
rogression in nonstented segments. In the overall ARRIVE
opulation, first-year ST reflected mostly DAPT compliance
long with anatomic and clinical factors known to increase
he risk of BMS ST, whereas ST in the second year seemed
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748ore related to biological markers (35). Extended DAPT use
ight help reduce the high incidence of late ST, but this
emains to be proven.
Moderate, nonischemic SVG lesions have been associated
ith both midterm and late cardiac events after coronary artery
ypass grafting (49–51). Prophylactic DES stenting of such
esions might provide preventive treatment against SVG ath-
rosclerosis progression. In a recent report, at 1-year follow-up
he use of PES stenting of moderate nonsignificant lesions in
ld SVGs compared with medical therapy alone was associated
ith a lower rate of disease progression as assessed by intra-
ascular ultrasound and a trend toward a lower cumulative
ncidence of major adverse cardiac events related to the target
VG (3% vs. 19%, respectively, p  0.09) (52).
tudy limitations. The main limitation of the current study is
ts observational nature and the lack of an appropriate control
roup. However, clinical outcomes in ARRIVE patients re-
eiving a PES in a vein graft were similar to those of the PES
rm of the SOS trial. To be in the ARRIVE registry, a patient
ad to receive a TAXUS Express stent, and this operator
hoice might have been influenced by the angiographic ap-
earance of the lesion and the clinical characteristics of the
atient. The incidence of MI might be underestimated, be-
ause systematic measurement of cardiac biomarkers was not
andated by the study protocol. The comparatively low (29%)
se of embolic protection in this series is consistent with the
ow penetration of this group of technologies, despite numer-
us trials showing reduction in adverse events when embolic
rotection is used during SVG intervention (53). The angio-
raphic data were based on visual assessment at each site and
ere not evaluated by an independent core laboratory. The MI
ates reported in the article represent clinical MI, but the rates
f peri-procedural MI were not collected.
onclusions
he ARRIVE patients undergoing SVG stenting have
ore baseline comorbidities and higher risk for adverse
vents compared with patients undergoing simple native
oronary artery stenting and even those undergoing complex
non-SVG) stenting. Although the 2-year repeat revascu-
arization rates in SVG patients are higher than in simple-
se patients, they are lower than historical revascularization
ates for BMS in SVGs. Outcomes in the ARRIVE SVG
roup are similar to that of the PES arm in the SOS trial
nd suggest that use of the TAXUS Express stent might
ave a lower repeat revascularization rate than when BMS
re used to treat focal SVG disease. These results provide
urther support for a large, prospective, multicenter RCT of
ES in SVG lesions (45,54).
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750ppendix
aseline Characteristic Variables Used in
redictor Modeling
Acute MI
Age 70 yrs
Bifurcation
Brachytherapy, prior
CABG, previous
Cardiogenic shock
Chronic total occlusion
Congestive heart failure (site reported as
NYHA functional class III)
Diabetes, insulin treated
Diabetes, not requiring insulin
Gender, male
Hypercholesterolemia (patient was
reported as having this condition and
may or may not have been receiving
medication for it)
Hypertension (patient was reported as
having this condition and may or may
not have been receiving medication
for it)
In-stent restenosis
IVUS post deployment
IVUS pre-deployment
LAD as target vessel
Left main disease
Left main stenting
Lesion 28 mm
Lesion calciﬁcation (moderate and
severe)
Lesion type B2/C
MI, previous
Multiple overlapping stents
Multiple stents per patient
Multivessel disease
Multivessel stenting
Ostial lesion
PCI, previous
Post-procedure dilation
Pre-procedure dilation
Pre-procedure TIMI ﬂow grade 0
Renal disease (Site reported as serum
creatinine 3.0 mg/dl or patient
on dialysis)
RVD 3 mm
Smoking at baseline
Stent inﬂation pressure 14 atm
Stroke, previous
Thienopyridine 12 months
Thienopyridine 6 months
Tortuosity, severe
Vein graft
Hazard ratios were assessed with the Cox proportional hazards regression model; backward
selection was used; the threshold to stay in the model was set at 0.10.
CABG  coronary artery bypass graft; IVUS  intravascular ultrasound; LAD  left anterior
descending artery; MImyocardial infarction; PCI percutaneous coronary intervention; RVDreference vessel diameter; TIMI Thrombolysis InMyocardial Infarction.
